Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

Presentation

Switching of OAC After PCI in A-fib Patients:RE-DUAL PCI Trial Subanalysis

December 04, 2019

Presentation

Impact of Preexisting and New-Onset A-fib on TAVR Outcomes

October 18, 2019

Presentation TCT Abstracts Posters 2019

Non-ST Elevation Myocardial Infarction in Hospitalized Patients With Atrial Fibrillation

Presenter: Pengyang Li

October 05, 2019

Presentation TCT Abstracts Posters 2019

In-hospital Outcomes of Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation: Nationwide Database Analysis

Presenter: Fangcheng Wu

September 29, 2019

Presentation TCT 2019

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Presenter: Amit Vora

September 28, 2019

Presentation TCT 2019

Reversal Strategies for Warfarin and NOACs: The Essentials

Presenter: Teresa Carman

September 27, 2019

Presentation TCT 2019

When and How to Switch to OAC Alone After PCI?

Presenter: Manesh Patel

September 27, 2019

Presentation TCT 2019

AFib Patients at High Ischemic Risk Post-PCI: Role of Triple Therapy or Potent P2Y12 Inhibition?

Presenter: Dominick Angiolillo

September 27, 2019

Presentation TCT 2019

PCI in Patients Requiring OAC: Which OAC and in Whom?

Presenter: Davide Capodanno

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presentation TCT 2019

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presenter: Robert Byrne

September 27, 2019

Presentation TCT 2019

TAVR and Concomitant Atrial Fibrillation: Case Presentation

Presenter: Fabian Nietlispach

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presentation TCT 2019

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presenter: C. Michael Gibson

September 27, 2019

Presentation TCT 2019

Endovascular Renal Sympathetic Denervation to Improve Heart Failure With Reduced Ejection Fraction: The IMPROVE HF-I Study

Presenter: Joost Daemen

September 27, 2019

Presentation TCT 2019

Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator in Patients with HFrEF and HFpEF: The AFR-PRELIEVE Trial

Presenter: Felix Mahfoud

September 27, 2019

Presentation TCT 2019

Epicardial LAAC to Reduce Atrial Fibrillation: AMAZE Rationale and Status

Presenter: DJ Lakkireddy

September 26, 2019

Presentation TCT 2019

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Presenter: Stephan Windecker

September 26, 2019

Presentation TCT 2019

Diagnostic Accuracy of Diastolic Pressure Ratio (dPR) using a Fiber-Optic Microcatheter

Presenter: Matthew Price

September 26, 2019

Presentation TCT 2019

Antithrombotic Therapy in PCI Patients With Atrial Fibrillation

Presenter: Marco Valgimigli

September 25, 2019

Presentation

Antithrombotic Therapy and CV Outcomes After TAVR in A-fib Patients

August 20, 2019

Presentation TVT 2019

Impact of Pre-Existing Atrial Fibrillation on Clinical Outcomes in Patients Who Underwent Balloon-Expandable Transcatheter Aortic Valve Replacement

Presenter: Hyungdon Kook

June 14, 2019

Advertisement

Switching of OAC After PCI in A-fib Patients:RE-DUAL PCI Trial Subanalysis

Impact of Preexisting and New-Onset A-fib on TAVR Outcomes

Non-ST Elevation Myocardial Infarction in Hospitalized Patients With Atrial Fibrillation

In-hospital Outcomes of Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation: Nationwide Database Analysis

AUGUSTUS: Hospitalizations From a 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation

Reversal Strategies for Warfarin and NOACs: The Essentials

When and How to Switch to OAC Alone After PCI?

AFib Patients at High Ischemic Risk Post-PCI: Role of Triple Therapy or Potent P2Y12 Inhibition?

PCI in Patients Requiring OAC: Which OAC and in Whom?

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

TAVR and Concomitant Atrial Fibrillation: Case Presentation

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Endovascular Renal Sympathetic Denervation to Improve Heart Failure With Reduced Ejection Fraction: The IMPROVE HF-I Study

Pilot Study to Assess Safety and Efficacy of a Novel Atrial Flow Regulator in Patients with HFrEF and HFpEF: The AFR-PRELIEVE Trial

Epicardial LAAC to Reduce Atrial Fibrillation: AMAZE Rationale and Status

AUGUSTUS ACS: A 2x2 Factorial Randomized Trial of Apixaban vs. Warfarin and Aspirin vs. Placebo in Patients With Atrial Fibrillation and an Acute Coronary Syndrome

Diagnostic Accuracy of Diastolic Pressure Ratio (dPR) using a Fiber-Optic Microcatheter

Antithrombotic Therapy in PCI Patients With Atrial Fibrillation

Antithrombotic Therapy and CV Outcomes After TAVR in A-fib Patients

Impact of Pre-Existing Atrial Fibrillation on Clinical Outcomes in Patients Who Underwent Balloon-Expandable Transcatheter Aortic Valve Replacement

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content